Innovent Biologics
China's leading biotech company pioneering affordable cancer immunotherapy
Company Overview
Innovent Biologics is one of China's most innovative biopharmaceutical companies, focused on developing affordable cancer immunotherapies and biologics. The company's PD-1 inhibitor Tyvyt was the first domestically developed PD-1 therapy approved in China. Innovent has extensive partnerships with Eli Lilly and other global pharma companies, and is expanding its pipeline into autoimmune diseases and metabolic disorders.
为什么关注这家公司
Innovent represents China's ambition to become a global leader in biologic drug innovation, not just manufacturing, with a pipeline that increasingly targets global markets.
核心关注领域
同行业公司
Signal Timeline
0 条No signals tracked yet for this company.
Signals will appear here as official announcements are indexed.
我们正在追踪该公司的官方渠道，信号将在发现后自动入库。
当该公司有新信号时，立即收到通知。